The first time I heard a researcher say the phrase programmed axon death, I sat up so fast I spilled my chamomile tea. For years I'd assumed nerve damage was a slow, passive wearing-down. Like a garden hose left in the sun until it cracks. But the science says something startlingly different: our nerves may carry a self-destruct button, a protein switch that fires when things go wrong, and the whole cascade takes minutes, not months.
That switch has a name. SARM1. And in the last handful of years it has gone from an obscure lab curiosity to one of the most exciting targets in neuropathy research, with several drug companies racing to develop the first medication that can turn it off.
I want to walk you through what SARM1 is, why researchers call this whole process “programmed axon death,” and what it might mean for people like us who live with peripheral neuropathy. I'll keep the science plain and honest. And I'll be clear about what's proven today, what's promising, and what's still years away from your pharmacy shelf.
The Old Story of Nerve Damage (and Why It Was Incomplete)
For most of the last century, doctors described nerve damage the same way they described a bruise: something bad happens to the nerve, and it slowly falls apart. Diabetes, chemotherapy, an injury, a vitamin deficiency — whatever the trigger, the nerve was thought to simply degrade over time from lack of nutrients or from ongoing chemical stress.
That picture wasn't wrong. It was just incomplete.
Researchers noticed something odd starting in the 1990s. When you cut an axon (the long fiber that carries signals down a nerve), the portion beyond the cut doesn't wither slowly. It survives for a day or two — completely normal on the outside — and then, in a matter of hours, it fragments. Beads on a string. Cleanly and rapidly. Almost like a demolition.
And even stranger: a lucky mouse strain called Wlds (short for “Wallerian slow”) had axons that survived for weeks after being cut. Not because the axons were tougher. Because the demolition program itself was broken.
That was the first hint that nerves don't just fall apart. They are actively taken apart by their own machinery.
What SARM1 Actually Is
SARM1 stands for Sterile Alpha and TIR Motif containing 1. It's a protein that sits quietly inside the axon, essentially dormant, all day every day. Think of it as a fire alarm in a hallway — necessary, useful, but only meant to fire when something is genuinely wrong.
SARM1 is a fire alarm, not a leak. Under normal conditions it sits dormant. When axon energy (NAD+) falls and NMN rises past a threshold, SARM1 wakes up and destroys NAD+ faster than the cell can rebuild it. The axon fragments within hours. This is a switch, not a slow decay.
The trigger that wakes SARM1 up involves a fuel molecule called NAD+ and a related molecule called NMN. Under healthy conditions, another enzyme called NMNAT2 keeps NAD+ high and NMN low inside the axon. As long as that ratio holds, SARM1 stays asleep.
But NMNAT2 is fragile. It has to be constantly resupplied from the nerve cell body, which sends it down the axon like a pipeline. If the axon is injured, choked off, or metabolically stressed, that pipeline slows down. NMNAT2 breaks down within hours. NMN rises. And when the NAD+/NMN ratio flips past a critical point — SARM1 wakes up.
What SARM1 does when it wakes up is remarkable. It is itself an enzyme, and its job is to destroy NAD+ as fast as it can. Within minutes, NAD+ inside the axon collapses. And when NAD+ collapses, so does the axon's ability to generate energy. Everything downstream fails. The membrane can no longer hold ion balances, calcium floods in, structural proteins break apart, and the axon fragments.
It is, in every meaningful sense, a programmed death. A controlled demolition of the axon.
Why Would Our Bodies Ever Evolve Such a Thing?
A fair question. Why would nerves come with a self-destruct?
The best guess is that programmed axon death evolved as a form of quality control. If part of an axon is badly damaged — infected, torn, or metabolically failing — it may be safer for the whole nervous system to demolish the failing piece cleanly than to let it linger and cause further trouble. The cell body can then attempt to regrow the axon fresh.
In young, healthy nerves recovering from an isolated injury, that logic works reasonably well. Cut a finger, damage a small nerve branch, and the demolition + regrowth cycle often succeeds.
The trouble comes when SARM1 fires in situations where it shouldn't. Chronic metabolic stress from diabetes. The prolonged chemical assault of chemotherapy. The steady damage of an inherited condition. In those cases, the demolition keeps happening, over and over, in nerves that never get a real chance to rebuild.
The Diseases Where SARM1 Is Suspected to Be a Major Player
Researchers now have strong evidence — mostly in animals, with growing human data — that SARM1 activation contributes to several kinds of nerve damage:
- Chemotherapy-induced peripheral neuropathy (CIPN) — vincristine, paclitaxel, and bortezomib all appear to activate SARM1. Mice missing SARM1 are dramatically protected from CIPN. Read more in our overview of chemo-induced neuropathy.
- Diabetic peripheral neuropathy — chronic high blood sugar disrupts axonal energy metabolism, and SARM1 appears to be one of the executors of that damage. See our guide to diabetic neuropathy.
- Traumatic nerve injury — the classic Wallerian degeneration scenario. SARM1 is the “demolition foreman.”
- Inherited neuropathies — some forms of Charcot-Marie-Tooth appear to involve SARM1 activation.
- Glaucoma, optic nerve injury, ALS, Alzheimer's, MS — SARM1's fingerprints have been found in a surprising number of neurodegenerative diseases beyond just peripheral neuropathy.
The common thread: any time axons are dying faster than they're being repaired, SARM1 is worth investigating as an accelerant.
The Human Genetic Evidence
Animal studies are compelling, but they're not the same as human evidence. Fortunately, the human side of the story is starting to fill in.
Rare gain-of-function SARM1 variants have been identified in a small percentage of patients with sporadic ALS — SARM1 that wakes up too easily.
Meanwhile, loss-of-function variants that dampen SARM1 appear to be neuroprotective. This is the human genetic pattern that makes SARM1 a promising drug target.
Researchers have found rare gain-of-function variants in the SARM1 gene in a small percentage of patients with sporadic amyotrophic lateral sclerosis (ALS). These variants make SARM1 more trigger-happy — it wakes up when it shouldn't. Conversely, loss-of-function variants that dampen SARM1 appear to be more common in healthy older adults than in patients with certain forms of nerve degeneration.
That's the kind of genetic pattern researchers look for when they want to know if a target is worth pursuing. If dialing SARM1 up causes disease and dialing it down is protective, then a drug that turns it down might slow or prevent that disease.
Why This Reframes the Whole Idea of Nerve Damage
Here's why programmed axon death matters even before any drug reaches the market.
It changes the mental model. For decades, we've thought of nerve damage as an accumulating chemical injury — as if the nerve were rusting slowly. That framing led to treatments focused on shoring up nutrition, controlling blood sugar, and neutralizing free radicals. Good things, all of them. But they treat the environment, not the demolition mechanism.
Programmed axon death says something different. It says that at a certain point — a metabolic tipping point — the nerve stops passively degrading and starts actively self-destructing. And that active phase is where the fastest damage happens.
It also explains something that has always puzzled people with neuropathy: why symptoms can seem to arrive in waves. Weeks of relative stability, then a bad month where new numbness spreads before things settle again. That pattern fits a threshold-based mechanism, not a gradual one.
The Difference Between Losing an Axon and Losing a Nerve Cell
This is worth pausing on, because it's the source of a lot of hope in the field.
A peripheral nerve cell has two main parts: the cell body (up in the spinal cord or in a ganglion near the spine) and the axon (the long fiber that stretches down to your foot or hand). Programmed axon death, as its name suggests, is about the axon fragment breaking down. It does not necessarily destroy the cell body.
If the cell body survives and the axon is what fragmented, then in principle the cell can grow a new axon. That regrowth is slow — about a millimeter a day at best — but it can happen. It's why some nerve injuries recover months to years later.
If, on the other hand, the cell body itself has been lost, no amount of SARM1 inhibition will grow it back. That's a different problem entirely.
The practical implication: SARM1 drugs, if they work in humans, are most likely to help in the window before too many cell bodies have died. Which is exactly the window where most people first notice their neuropathy symptoms — small early damage, before things become severe. For a fuller look at how nerves stage progression, see what are the stages of neuropathy.
What SARM1 Inhibitors Look Like Today
Several companies are working on this. The two most-mentioned in the scientific literature are Disarm Therapeutics (acquired by Eli Lilly in 2019) and Nura Bio. Others have joined more recently, and the patent literature shows an active race.
The compounds are mostly small molecules that fit into a specific binding pocket on the SARM1 enzyme and prevent it from destroying NAD+. Some target the “TIR” domain (the business end of the enzyme). Others try to lock SARM1 into its dormant shape so it can't be activated even under stress.
As of 2026, no SARM1 inhibitor is FDA-approved for any condition. Early clinical trials — mostly Phase 1 safety studies — are underway or planned. The first indications being pursued are usually CIPN prevention (given alongside chemotherapy) and traumatic nerve injury, because those are relatively short-duration situations where a drug just needs to work for weeks or months.
Longer-duration uses — treating diabetic neuropathy, for example, where a drug would need to be taken for years — will come later, if at all.
What This Means for Prevention, Not Just Treatment
One of the most interesting aspects of the SARM1 story is that it points toward prevention, not just treatment. If we can identify people at high risk for nerve damage — someone about to start neurotoxic chemotherapy, someone with early diabetes, someone with an inherited neuropathy — and give them a SARM1 inhibitor before axons start to die, we might prevent damage from ever taking hold.
That's a fundamentally different treatment philosophy from what we have now, which is mostly reactive: nerve damage happens, and then we manage symptoms with medications like gabapentin, alpha-lipoic acid, and topical treatments.
Prevention is the holy grail. It's also the hardest thing to prove in a clinical trial, because you have to enroll patients who don't yet have the disease and follow them long enough to see whether the drug prevented it.
The NAD+ Supplements Question
Because SARM1 destroys NAD+, and because NAD+ boosting supplements like nicotinamide riboside and NMN have become popular, I get asked constantly whether these supplements might help protect nerves.
Do not treat NAD+ boosters (NMN, nicotinamide riboside) as neuropathy prevention.
Once SARM1 is active it destroys NAD+ faster than any supplement can restore it — and rising NMN is one of the signals that turns SARM1 on. Talk to your doctor before adding any NAD+-boosting supplement, especially if you have an active neurodegenerative condition.
The honest answer is: probably not in the way you'd hope.
Once SARM1 is activated, it can chew through NAD+ faster than any supplement can replenish it. And here's a wrinkle — NMN supplementation may actually be problematic in some contexts, because rising NMN is one of the signals that activates SARM1 in the first place. In healthy tissue that isn't a problem. In stressed nerves, it might be.
Some early animal work suggests nicotinamide (a different form of B3) may modestly delay Wallerian degeneration. But we're talking about small effects, and the human trials haven't been done to prove out any of this for neuropathy. I would not spend money on NAD+ boosters expecting them to protect your nerves. Talk to your doctor before starting any of these, especially if you have an active neurodegenerative condition.
How Doctors Might Use SARM1 Testing (Eventually)
One tantalizing possibility down the road: a blood test that measures SARM1 activity, or measures the breakdown products SARM1 leaves behind, could tell doctors whether a person's nerves are actively dying versus stable.
A blood test that captures SARM1 activity in real time could one day tell doctors whether your nerves are being actively demolished or are stable — turning static snapshots (like EMG) into a moving picture. This biomarker work is early, but it is running in parallel with SARM1 drug development.
Right now, we mostly infer nerve damage from symptoms and from tests like EMG and nerve conduction studies, which measure the electrical function of nerves. Those tests tell you the current state of your nerves — but they're not very good at telling you which direction things are moving quickly.
A “SARM1 activity” biomarker could theoretically say: your nerves are actively being demolished right now, this is an urgent situation — or — your nerves are stable, no active demolition, we can focus on symptom management. That would be transformative for how we make decisions about aggressive treatments.
This is speculative. But biomarkers of nerve damage are actively being developed, and I'll be writing about them as they come.
What You Can Do Right Now
Let me be clear about the practical situation as of 2026.
Stay below the SARM1 threshold — that is the plan today.
- Tight blood-sugar control if you have diabetes or prediabetes
- Correct B12, B1, and B6 deficiencies (blood tests before supplementing)
- Manage thyroid, autoimmune, and other underlying triggers
- Move daily — walking, gentle strength work, whatever your feet tolerate
- Track symptoms so your care team sees the trajectory, not just the snapshot
There is no SARM1 inhibitor you can buy or ask your doctor for. There is no supplement that meaningfully blocks SARM1. There is no diet that specifically targets programmed axon death. If someone is selling you a “SARM1-blocker supplement,” they are ahead of the science.
What the SARM1 research does support, indirectly, is what we already know: reducing metabolic stress on your nerves matters. That means keeping blood sugar tight if you have diabetes, avoiding neurotoxic substances when possible, correcting vitamin deficiencies (especially B12), and treating underlying conditions like thyroid disease or autoimmune disorders that may be triggering the cascade.
All of the things we talk about in our guides to natural remedies for peripheral neuropathy and home treatment approaches are still what we've got. They aren't glamorous. But if programmed axon death is a threshold-based process, then anything that keeps your nerves further from the threshold — better blood sugar, better nutrition, better circulation, less inflammation — is buying you time until the next generation of drugs arrives.
What to Watch For in the Coming Years
If you follow neuropathy research the way I do (in a comfortable chair with tea, not in a lab), here are the milestones I'm looking for:
- First Phase 2 SARM1 inhibitor trial results. Almost certainly in CIPN prevention first. Watch for readouts in the late 2020s.
- Long-term safety data. Because SARM1 may have some healthy immune-signaling roles beyond axon death, we need to see what happens when it's blocked for months at a time.
- Combination trials. SARM1 inhibitors may work best paired with something that helps axons regrow — think growth factors, or exercise-based rehab programs.
- Diabetic neuropathy trials. These will be harder to run but potentially transformative if they succeed.
- Biomarker development. As I mentioned above, a way to measure ongoing axon death would change everything about how we manage neuropathy.
The Emotional Weight of a Discovery Like This
I'll be honest. When I first learned about programmed axon death, I had two very different reactions in the same day.
The first was excitement — they've found the mechanism, they can stop this. The second, a few hours later, was a heavier feeling — if it's this precise a switch, why is it firing in me? What has been happening in my feet all these years?
Both reactions are valid. It's okay to feel hopeful and it's okay to feel grief when new science shows you, in vivid detail, exactly what has been going wrong in your body. I sat with both feelings for a while. And then I made another cup of tea and reminded myself that knowing the mechanism, even without a cure yet, is more than we had ten years ago.
The women and men who first identified SARM1's role in axon death did not do it in the hope of writing a research paper. They did it in the hope of one day telling someone with neuropathy: we can stop this. That day is not here yet. But the fact that it is even a plausible sentence to write is a kind of hope I did not have twenty years ago.
Frequently Asked Questions
Is there a SARM1 inhibitor I can take right now?
No. As of 2026, no SARM1 inhibitor has been approved for use in humans. Several are in early clinical trials, mostly for chemotherapy-induced neuropathy and nerve injury. Approval for widespread use is likely still years away.
Will SARM1 drugs reverse damage that has already happened?
Probably not existing damage. SARM1 inhibitors are expected to stop the active demolition process — meaning they may prevent further axon loss and give the surviving nerves a chance to regrow. Damage to the nerve cell body itself is not repaired by SARM1 inhibition.
Are NMN or nicotinamide riboside supplements a good substitute?
No. Once SARM1 is activated, it destroys NAD+ faster than any supplement can restore it. NMN in particular may even nudge the SARM1 activation signal in the wrong direction under some conditions. There is no consumer supplement that reliably blocks SARM1. Please talk with your doctor before adding any new supplement.
Does SARM1 explain all types of neuropathy?
No. SARM1 appears to be an important contributor to many types of nerve damage, especially those involving axon injury and metabolic stress. But some forms of nerve damage involve inflammation, autoimmune attack, or destruction of the nerve cell body itself — situations where SARM1 is not the main driver.
How is SARM1 different from Wallerian degeneration?
Wallerian degeneration is the observed process of an axon fragmenting after injury. SARM1 is the enzyme researchers now know executes that process. In other words, Wallerian degeneration is the phenomenon, and SARM1 is the machinery that carries it out.
Can lifestyle changes affect SARM1 activity?
Probably yes, indirectly. Anything that reduces metabolic stress on your nerves — better blood sugar control, adequate B vitamins, avoiding neurotoxins — likely keeps your nerves further from the threshold that activates SARM1. Direct SARM1-targeted lifestyle interventions do not yet exist.
Where can I follow the research?
ClinicalTrials.gov is the best source for ongoing SARM1 inhibitor trials. Search for “SARM1” or the individual company names. Peer-reviewed research is heavily represented on PubMed. I try to translate the important findings into plain language on this site whenever a major result publishes.
Nerve science has moved faster in the last decade than in the previous fifty years combined. That doesn't mean the answer is around the corner. But it does mean that if you are living with neuropathy today, and doing what you can to slow it, you are also giving yourself the best chance of being ready when the next generation of treatments arrives. That is worth something. That is worth a lot.
About the Author
